Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Frouke T. van Beek"'
Autor:
Karlijn Groen, Joanne J. van der Vis, Aernoud A. van Batenburg, Karin M. Kazemier, Marjolein J.W. de Bruijn, Ralph Stadhouders, Pascal Arp, Annemieke J.M.H. Verkerk, Angela E. Schoemaker, Charlotte I. de Bie, Maarten P.G. Massink, Frouke T. van Beek, Jan C. Grutters, Leonie J.M. Vergouw, Coline H.M. van Moorsel
Publikováno v:
ERJ Open Research, Vol 10, Iss 1 (2024)
Introduction Pulmonary fibrosis is a severe disease which can be familial. A genetic cause can only be found in ∼40% of families. Searching for shared novel genetic variants may aid the discovery of new genetic causes of disease. Methods Whole-exom
Externí odkaz:
https://doaj.org/article/8c3a99dc938b4757bc353fa3c9736810
Autor:
Nynke A. Kampstra, Paul B. van der Nat, Lea M. Dijksman, Frouke T. van Beek, Daniel A. Culver, Robert P. Baughman, Elisabetta A. Renzoni, Wim Wuyts, Vasilis Kouranos, Pieter Zanen, Marlies S. Wijsenbeek, Marinus J.C. Eijkemans, Douwe H. Biesma, Philip J. van der Wees, Jan C. Grutters
Publikováno v:
ERJ Open Research, Vol 5, Iss 4 (2019)
Our study presents findings on a previously developed standard set of clinical outcome data for pulmonary sarcoidosis patients. We aimed to assess whether changes in outcome varied between the different centres and to evaluate the feasibility of coll
Externí odkaz:
https://doaj.org/article/4341615797da410cb32c14a6a4eee893
Autor:
Coline H.M. van Moorsel, Tamera J. Corte, An Zhao, Christopher J. Brereton, Katarina Pontoppidan, Annalisa De Liperi, Peter Hopkins, Alessandro Taliani, Bahareh Gholipour, Frouke T. van Beek, Mark Jones, Marcel Veltkamp, David Barber, Nesrin Mogulkoc, Laura Tavanti, Athol U. Wells, Arjun Nair, Eyjolfur Gudmundsson, Hendrik W. van Es, Yuben Moodley, Iain A. Stewart, Joseph Jacob, Daniel C. Alexander, Chiara Romei, Helen E. Jo, Recep Savaş, Omer Unat, Sam M. Janes
Publikováno v:
ERJ Open Research, Vol 7, Iss 3 (2021)
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research
article-version (VoR) Version of Record
[No Abstract Available]
Wellcome Trust [209553/Z/17/Z]; UCLH Biomedical Research Centre
This study was supported by Wellcome Trust grant 209553/Z/17/Z and the UCLH Biomedical Research Centre. Funding information for this article has been de
Wellcome Trust [209553/Z/17/Z]; UCLH Biomedical Research Centre
This study was supported by Wellcome Trust grant 209553/Z/17/Z and the UCLH Biomedical Research Centre. Funding information for this article has been de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f67e61204925544e9ea43ed9ad8a3a0f
http://hdl.handle.net/10044/1/98273
http://hdl.handle.net/10044/1/98273
Autor:
Paul B. van der Nat, Douwe H. Biesma, J.C. Grutters, Philip J. van der Wees, Frouke T. van Beek, Nynke A. Kampstra
Background Prednisone is used as first-line therapy for patients with pulmonary sarcoidosis. There is however no clear association between prednisone dose and FVC change in patients with pulmonary sarcoidosis. In order to improve our standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3fb09135ba0e33664ea0c7c4e0888c5
https://doi.org/10.21203/rs.3.rs-423129/v1
https://doi.org/10.21203/rs.3.rs-423129/v1
Autor:
Recep Savaş, Iain A. Stewart, Omer Unat, Marcel Veltkamp, Eyjolfur Gudmundsson, Hendrik W. van Es, Coline H.M. van Moorsel, Mark Jones, Frouke T. van Beek, An Zhao, Christopher J. Brereton, Arjun Nair, Athol U. Wells, Katarina Pontoppidan, Joseph Jacob, Daniel C. Alexander, Nesrin Mogulkoc, Bahareh Gholipour, Sam M. Janes
Publikováno v:
EClinicalMedicine, Vol 38, Iss, Pp 101009-(2021)
EClinicalMedicine
EClinicalMedicine
Background: Idiopathic pulmonary fibrosis (IPF) and pleuroparenchymal fibroelastosis (PPFE) are known to have poor outcomes but detailed examinations of prognostic significance of an association between these morphologic processes are lacking. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab072f560407a45b6cb125c74a04c9e
https://hdl.handle.net/11454/76506
https://hdl.handle.net/11454/76506
Autor:
Coline H.M. van Moorsel, E. P. Judge, Alex J Procter, Joseph Barnett, Frouke T. van Beek, Gary Cross, Athol U. Wells, Marcel Veltkamp, Joseph Jacob, Wouter van Es, Maria Kokosi, Bahareh Gholipour, Nesrin Mogulkoc, Mark Jones, Teresa Burd, Recep Savaş, Andre Altmann, Leon M Aksman, Sujal R. Desai, Christopher J. Brereton, Selen Bayraktaroglu
Publikováno v:
Thorax
Aims Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1120dd63c40c45bc37a34f696d6ac1a9
https://hdl.handle.net/11454/62098
https://hdl.handle.net/11454/62098
Autor:
Frouke T. van Beek, Marcel Veltkamp, Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Ruth G.M. Keijsers, Heleen A. Crommelin, Vera H.M. Deneer
Publikováno v:
Respiratory Medicine. 138:S7-S13
Background Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b7dd966ccd16e45f2e107695c538102
https://doi.org/10.1016/j.rmed.2018.02.009
https://doi.org/10.1016/j.rmed.2018.02.009
Autor:
Elisabetta A. Renzoni, Philip J. van der Wees, Frouke T. van Beek, Nynke A. Kampstra, Jan C. Grutters, Paul B. van der Nat, Wim A. Wuyts, Lea M. Dijksman, Robert P. Baughman, Douwe H. Biesma, Pieter Zanen, Vasilis Kouranos, Marinus J.C. Eijkemans, Marlies S. Wijsenbeek, Daniel A. Culver
Publikováno v:
ERJ Open Research
BMJ open [E], 5(4). BMJ Publishing Group
ERJ Open Research, 5
ERJ Open Research, Vol 5, Iss 4 (2019)
ERJ Open Research, 5, 4
ERJ Open Research, 5(4):00094-2019. European Respiratory Society
BMJ open [E], 5(4). BMJ Publishing Group
ERJ Open Research, 5
ERJ Open Research, Vol 5, Iss 4 (2019)
ERJ Open Research, 5, 4
ERJ Open Research, 5(4):00094-2019. European Respiratory Society
Our study presents findings on a previously developed standard set of clinical outcome data for pulmonary sarcoidosis patients. We aimed to assess whether changes in outcome varied between the different centres and to evaluate the feasibility of coll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa05dd08cc3ea90a1245c010c046ef72
http://europepmc.org/articles/PMC6819983
http://europepmc.org/articles/PMC6819983
Autor:
Philip J. van der Wees, Paul B. van der Nat, Frouke T. van Beek, Daniel A. Culver, Douwe H. Biesma, Jan C. Grutters, Elisabetta A. Renzoni, Vaslis Kouranos, Marlies S. Wijsenbeek, Nynke A. Kampstra, Wim A. Wuyts, Robert P. Baughman
Publikováno v:
BMJ Open Respiratory Research
BMJ open respiratory research, 6
BMJ Open Respiratory Research, 6(1):UNSP e000394. BMJ Publishing Group
BMJ open respiratory research, 6, 1
BMJ open respiratory research, 6
BMJ Open Respiratory Research, 6(1):UNSP e000394. BMJ Publishing Group
BMJ open respiratory research, 6, 1
IntroductionRoutine and international comparison of clinical outcomes enabling identification of best practices for patients with pulmonary sarcoidosis is lacking. The aim of this study was to develop a standard set of outcome measures for pulmonary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cd0f9a6735ce588de01c0334031f999
https://doi.org/10.1136/bmjresp-2018-000394
https://doi.org/10.1136/bmjresp-2018-000394
Autor:
Anand Devaraj, Joseph Jacob, Andre Altmann, Ronald A. Karwoski, Eoin P. Judge, Angelo De Lauretis, Hendrik W. van Es, Teresa Burd, Maria Kokosi, Ryan Clay, Elisabetta A. Renzoni, Teng Moua, Srinivasan Rajagopalan, Tobias Peikert, Frouke T. van Beek, Marcel Veltkamp, Brian J. Bartholmai, Toby M. Maher, Coline H.M. van Moorsel, Athol U. Wells, Fabien Maldonado
Publikováno v:
The European Respiratory Journal
The advent of antifibrotic agents [1, 2] as standard of care in idiopathic pulmonary fibrosis (IPF) requires that new non-inferiority IPF drug trials will need to identify smaller declines of forced vital capacity (FVC). Marginal annualised FVC decli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a23b58ea706253718cf11c6ed22bd7